A 3-Plex Methylation Assay Combined with the <i>FGFR3</i> Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine

Abstract

The combination of methylation and FGFR3 assays efficiently detects recurrent bladder cancer without the need for stratification of patients regarding methylation/mutation status of the primary tumor. We conclude that the sensitivity of this combination is in the same range as cystoscopy and paves the way for a subsequent study that investigates a modified surveillance protocol consisting of the urine test followed by cystoscopy only when the urine test is positive.